Market Cap (In ILA)
95.25 Million
Revenue (In ILA)
-
Net Income (In ILA)
-29.06 Million
Avg. Volume
22.96 Thousand
- Currency
- ILA
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 350.0-1600.0
- PE
- -
- EPS
- -
- Beta Value
- 1.105
- ISIN
- IL0011319527
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Oren Hershkovitz Ph.D.
- Employee Count
- -
- Website
- https://www.enlivex.com
- Ipo Date
- 2019-07-22
- Details
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
More Stocks
-
ACADAcadeMedia AB (publ)
ACAD
-
603922
-
6160Cipherlab Co.,Ltd.
6160
-
WDRP
-
DREAMFOLKSDreamfolks Services Limited
DREAMFOLKS
-
SLRRF
-
603876
-
002343Ciwen Media Co.,Ltd.
002343